Gilead Sciences, Inc. is listed among the 15 Best Boring Dividend Stocks to Buy. Truist analyst initiated coverage of Gilead with a Buy rating and $140 price target, citing strength in HIV portfolio and oncology efforts driving future growth. Core business shows strong results with HIV treatments Biktarvy and Descovy contributing to revenue growth.

Liver disease treatments also saw sales rise, contributing to overall growth. Gilead’s diversification strategy aims to reduce dependence on HIV segment over time. The company is engaged in discovering, developing, and commercializing innovative medicines for unmet medical needs. While Gilead has investment potential, certain AI stocks may offer greater upside potential and less downside risk.

Read more at Yahoo Finance: Gilead (GILD) Earns Buy Rating at Truist as HIV Franchise Continues to Deliver